Welcome to our dedicated page for Akari Therapeutics Plc news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc stock.
Akari Therapeutics Plc (AKTX) is a clinical-stage biopharmaceutical company developing complement inhibitor therapies for orphan autoimmune and inflammatory diseases. The company's news flow typically centers on clinical development milestones, preclinical data presentations, patent filings, and corporate financing activities that support its drug development programs.
Investors tracking Akari follow announcements related to its lead candidate Coversin, a C5 complement inhibitor derived from tick proteins. Clinical trial updates, scientific presentations at medical conferences, and regulatory developments provide insight into the company's progress advancing therapeutics through the drug development pipeline. Manufacturing updates signal preparation for potential commercial-scale production, while patent filings indicate efforts to protect intellectual property around complement inhibition technologies.
As a clinical-stage company without commercial revenue, financing announcements carry particular significance for Akari. Equity offerings, registered direct offerings, and other capital-raising activities provide the funding necessary to advance clinical programs and maintain operations. Scientific advisory board appointments and leadership changes also generate news that may signal strategic direction or bolster expertise in specific therapeutic areas.
Conference presentations and abstract acceptances offer windows into preclinical and clinical data before formal publication. For biopharmaceutical investors, these events provide early signals about drug candidate efficacy, safety profiles, and mechanism of action validation. The orphan disease focus means that even incremental progress in rare autoimmune conditions can have meaningful implications for patient populations with limited treatment options.
Akari Therapeutics (Nasdaq: AKTX), an oncology biotechnology company, will participate in the Virtual Investor Closing Bell Series on September 4, 2025 at 4:00 PM ET. During the event, CEO Abizer Gaslightwala will present a corporate overview focusing on the company's innovative payload platform for developing next-generation antibody drug conjugates (ADCs) in cancer treatment.
The event will feature a moderated discussion followed by a live Q&A session with investors. The presentation will be accessible through a live video webcast on the company's website, with a replay available for 90 days after the event.
Akari Therapeutics (Nasdaq: AKTX), a biotechnology company focused on developing novel Antibody Drug Conjugates (ADCs) for cancer treatment, has announced its participation in the upcoming Webull Financial Corporate Connect Webinar Series: Biotech/MedTech virtual event.
The company's President and CEO, Abizer Gaslightwala, will present on Tuesday, August 19, 2025, at 2:00 PM ET. The event is part of a broader virtual conference running from August 19-21, 2025.
Akari Therapeutics (Nasdaq: AKTX), an oncology biotechnology company, has released a Virtual Investor "What This Means" segment featuring CEO Abizer Gaslightwala. The presentation focuses on the company's novel spliceosome modulator payload, PH1, which is being developed as part of their antibody drug conjugates (ADCs) platform for cancer treatment.
During the segment, Gaslightwala discussed ongoing research efforts to understand how the PH1 payload can disrupt key drivers of cancer cell growth, highlighting the company's commitment to advancing their oncology pipeline.
Akari Therapeutics (NASDAQ:AKTX) is advancing research on its novel antibody drug conjugate (ADC) payload PH1, a spliceosome modulator designed for cancer treatment. The company highlighted that PH1 demonstrates multiple mechanisms of action, including cancer cell death induction and immune system activation against tumors.
Key features of PH1 include its ability to target cancers driven by oncogenic factors like KRAS, BRAF, and FGFR3, reduced off-target toxicity through engineered linker technology, and resistance to standard efflux transporters. The company expects to release new preclinical data on PH1's impact against a key oncogenic driver before the end of 2025.
Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on developing novel immuno-oncology payload antibody drug conjugates (ADCs), announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.
During the event, President and CEO Abizer Gaslightwala shared insights about his career journey, his commitment to the company, and his enthusiasm for Akari's development programs. The presentation is now accessible on-demand through virtualinvestorco.com and the company's investor relations website.
Akari Therapeutics (Nasdaq: AKTX), an oncology biotechnology company, has released a Virtual Investor segment discussing their recently granted India Patent No. 562,919. The patent, titled "Thailanstatin Analogs," covers the company's PH1 payload, proprietary cleavable and non-cleavable linkers, and ADC technology for cancer treatment applications.
The segment features CEO Abizer Gaslightwala explaining the significance of this patent protection for their immuno-oncology antibody drug conjugates (ADCs) technology platform.
Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on developing novel payload antibody drug conjugates (ADCs), has released a "Meet the Team" video featuring Mark F. Kubik, their newly appointed Head of Business Development – Oncology. The video, which showcases Kubik, an industry leader known for his oncology expertise and successful transaction record leading to multiple approved therapeutic products, is now available on the company's website under the Investors section.
Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on developing novel payload antibody drug conjugates (ADCs), has announced its participation in the upcoming LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar. President and CEO Abizer Gaslightwala will present and discuss recent corporate developments on Thursday, May 29, 2025, at 2:20 PM ET. The presentation will be accessible through a webcast, with registration available for interested participants.
Akari Therapeutics (NASDAQ: AKTX) reported Q1 2025 financial results and provided updates on its ADC development program. The company is developing novel Antibody Drug Conjugates with immuno-oncology payloads for cancer treatment, with its lead asset AKTX-101 targeting Trop2. The company appointed Mark Kubik as Head of Business Development - Oncology.
Financial highlights include a reduced net loss of $3.7 million compared to $5.6 million in Q1 2024. R&D expenses decreased to $0.8 million from $2.3 million, while G&A expenses dropped to $2.7 million from $3.7 million. The company held $2.6 million in cash as of March 31, 2025, with an additional $4.0 million received in April from a March 2025 offering that raised $6.0 million net.
Key upcoming milestones include presenting preclinical data for their PH1 payload ADC in H2 2025, exploring AKTX-101 in various solid tumors, and seeking strategic partnerships.
FAQ
What is the current stock price of Akari Therapeutics Plc (AKTX)?
What is the market cap of Akari Therapeutics Plc (AKTX)?
